Kaye J considered that it was for those reasons that the courts have required that a defendant is 'bound by the meanings put forward by the plaintiff, or meanings which are either a "variant" of the plaintiff's meanings, a "nuance" of the plaintiff's meanings, or, at most, are not substantially different from those meanings' [25]. Kaye J then applied those tests to the case before him, bearing in mind the underlying reasons for the tests. His Honour concluded that the defendants' imputations were not substantially different from the plaintiff's imputation and should not be struck out. His Honour considered that the principal thrust of the article was the allegation that the directors of Solagran purchased shares in the company for a significant period before they released details of the successful clinical trial of Ropren to the market. There were 'two intertwined threads joined in the article. The first thread was the purchase of the shares, and, tied with that thread, was the purchase of the shares by the defendants before price sensitive information had been released to the market' [44]. Kaye J considered that the plaintiff had 'chosen to extract one of the two threads - the non-disclosure of the information - and restrict his innuendo to one aspect of that allegation' [44]. On the other hand, the defendants had pleaded their innuendo to the two intertwined threads. His Honour considered that in that way there is a necessary and close connection between the subject matter of the defendants' imputation and the subject matter of the plaintiff's imputation. His Honour considered that it would be unfair if the defendants were shut out from pleading a defence directed to an imputation focussing on non-disclosure and purchase of shares. His Honour said: